Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In vivo biological standardization of Dermatophagoides allergen extracts
2024-514108-15-01Phase 2Authorised
- Sponsor
- Asacpharma
- Start
- Mar 2025
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of dermatophagoides pteronyssinus and dermatophagoides farinae in house dust mite allergy (2 arms), sponsored by Asacpharma. Planned start Mar 2025; status: authorised.
02
Drugs
dermatophagoides pteronyssinusdermatophagoides farinae
03
Conditions
house dust mite allergy
Beyond the preview
Go deeper on 2024-514108-15-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514108-15-01.